Greenwich LifeSciences (GLSI) announced the expansion of its FLAMINGO-01 clinical trial, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, to Portugal. The company’s application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, and the US. Breast cancer is the leading cause of death from cancer in women in Portugal with 2,211 deaths in 2022.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI:
- Greenwich LifeSciences expands Phase 3 Flamingo-01 clinical trial to Ireland
- Greenwich LifeSciences granted Fast Track designation for GLSI-100 by FDA
- Greenwich LifeSciences initiated with an Outperform at Noble Capital
- Greenwich LifeSciences to build out internal clinical trial operations team
- Greenwich LifeSciences announces expansion of Flamingo-01 into Romania